Chemistry Reference
In-Depth Information
26. Stahl, P. and Wermuth, C. (Eds.), (2002)
Handbook of Pharmaceutical Salts: Properties,
Selection and Use
, Wiley-VCH Verlag GmbH, Zürich, Switzerland.
27. Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., and Trappitt, G. (2011)
Pharmaceutical co-crystals: an overview.
Int. J. Pharm.
, 419:1-11.
28. Yu, L. (2001) Amorphous pharmaceutical solids: preparation, characterization and stabili-
zation.
Adv. Drug Deliv. Rev.
, 48:27-42.
29. Hancock, B. and Zogra
, G. (2000) Characterization and signi
cance of the amorphous state
12.
30. Stevenson, C., Bennett, D., and Lechuga-Ballesteros, D. (2005) Pharmaceutical liquid
crystals: the relevance of partially ordered systems.
J. Pharm. Sci.
, 94:1861-1880.
31. Branchu, S., Rogueda, P., Plumb, A., and Cook, W. (2007) A decision-support tool for the
formulation of orally active, poorly soluble compounds.
Eur. J. Pharm. Sci.
, 22:128-139.
32. Sjögren, E., Bolger, M., Lukacova, V., Weitschies, W., Wilson, C., Augustijns, P.,
Reppas,C.,Tannergren,C.,Becker,D.,Holm,R.,Juretschke,H.,Zane,P.,Brewster,
M., Van Peer, A., Münster, U., Abrahamsson, B., Flanagan, T., Lindahl, A., Kubbinga,
M., Heinen, C., Harwood, M., Rostami, A., Neuhoff, S., Nguyen, M., Lennernäs, H., and
Langguth, P. (2014)
In vivo
methods for drug absorption and API/formulation studies.
Eur. J. Pharm. Sci.
33. Mackie, C., Mortishire-Smith, R., Wuyts, K., Lampo, A., and Brewster, M. (2008) Assessing
solid dosage form feasibility and solubility/dissolution rate limitations for drug candidates:
early solution-suspension comparisons in the rat.
American Association of Pharmaceutical
Scientists (AAPS) Annual Meeting and Exposition, Atlanta, GA
, poster T2100.
34. Saxena, V., Panicucci, R., Joshi, Y., and Garad, S. (2009) Developability assessment in
pharmaceutical industry: an integrated group approach for selecting developable candidates.
J. Pharm. Sci.
, 98:1962-1979.
35. Maas, J., Kamm, W., and Hauck, G. (2007) An integrated early formulation strategy: from hit
evaluation to preclinical candidate pro
ling.
Eur. J. Pharm. Biopharm.
, 66:1-10.
36. Muenster, U., Pelzetter, C., Backensfeld, T., Ohm, A., Kuhlmann, T., Mueller, H., Lustig, K.,
Keldenich, J., Greschat, S., Göller, A., and Gnoth, M. (2011) Volume to dissolve applied
dose (VDAD) and apparent dissolution rate (ADR): tools to predict
in vivo
bioavailability
from orally applied drug suspensions.
Eur. J. Pharm. Biopharm.
, 78:522
in pharmaceutical systems.
J. Pharm. Sci.
, 86:1
-
530.
37. Leuner, C. and Dressman, J. (2000) Improving drug solubility for oral delivery using solid
dispersions.
Eur. J. Pharm. Biopharm.
, 50:47-60.
38. Serajuddin, A. (1999) Solid dispersion of poorly water-soluble drugs: early promises,
subsequent problems and recent breakthroughs.
J. Pharm. Sci.
, 88:1058-1066.
39. Janssens, S. and Van den Mooter, G. (2009) Physical chemistry of solid dispersions.
J.
Pharm. Pharmacol.
, 61:1571-1586.
40. Dokoumetzidis, A. and Macheras, P. (2006) A century of dissolution research: from Noyes-
Whitney to the biopharmaceutical classification system.
Int. J. Pharm.
, 321:1-11.
41. Verreck, G. and Brewster, M. (2004) Melt extrusion-based dosage forms: excipients and
processing conditions for pharmaceutical formulations.
Sustained Release Formulations with
Lipid Based Excipients
, 97th Bulletin Technique Gattefosse, Craig, D. (Ed.), Gattefosse,
Saint-Priest, France, pp. 85-95.
42. Craig, D. (2002) The mechanism of drug release from solid dispersions in water-soluble
polymers.
Int. J. Pharm.
, 231:131-144.
-
